ASX Share rice
Sat 15 May 2021 - 03:50:am (Sydney)

M7T Share Price

MACH7 TECHNOLOGIES LIMITEDM7THealth Care Equipment & Services

M7T Company Information

Name:

Mach7 Technologies Limited

Sector:

Healthcare

Industry:

Health Information Services

GIC Industry:

Health Care Technology

GIC Sub Industry:

Health Care Technology

Address:

120 Kimball Avenue South Burlington VT United States 05403

Phone:

802 861 7745

CEO, MD & Director:

Mr. Michael Lampron

Global CFO & Corp. Sec.:

Ms. Jennifer Lee Pilcher C.A., CA, BBS, AGIA

VP of Global Sales:

Mr. John Marshall

VP of Marketing:

Mr. Bob Tranchida

Head of People & Culture:

Ms. Sue Stasny

Chief Product Officer:

Mr. Steve Rankin

Company Overview:

Mach7 Technologies Limited provides enterprise imaging data sharing, storage, and interoperability solutions for healthcare enterprises worldwide. The company operates through two segments, Sale of Software Licenses and Provision of Professional Services. It offers Management Studio that enables healthcare delivery organizations to own, archive, and communicate imaging data across the enterprise and connect that data with the electronic medical record. The company's Management Studio comprises enterprise imaging platform, vendor neutral archive, communication workflow engine, routing engine, fetching engine, and migration engine products. It also provides Diagnostic Studio that includes a suite of solutions to drive specialty workflows. The company's Diagnostic Studio solutions include PACS and QC solution; and Universal Worklist. In addition, the company offers Clinical Studio, which provides access to view, navigate, review, and share patient medical data over the Web and across the enterprise. Its Clinical Studio solutions consist of clinical portal, clinical viewer, image sharing, and procedure import/export products, as well as iModality, a mobile medical image capture using smart device technology. Further, the company provides professional services, such as implementation and training, data migration, support, and maintenance services; and archive migration services. Mach7 Technologies Limited was founded in 2007 and is based in South Burlington, Vermont.

M7T Share Price Information

Shares Issued:

235.59M

Market Capitalisation:

$248.55M

Revenue (TTM):

$16.89M

Revenue Per Share (TTM):

$0.08

Earnings per Share:

$0.001

Profit Margin:

-0.4547

Operating Margin (TTM):

$-0.50

Return On Assets (TTM):

$-0.09

Return On Equity (TTM):

$-0.18

Quarterly Revenue Growth (YOY):

-0.218

Gross Profit(TTM):

$6.25M

Diluted Earnings Per Share (TTM):

$-0.036

M7T CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-79,459

Change To Liabilities:

$1.80M

Total Cashflow From Investing Activities:

$-79,459

Net Borrowings:

$-773,772

Net Income:

$169.29K

Total Cash From Operating Activities:

$4.75M

Depreciation:

$2.10M

Other Cashflow From Investing Activities:

$-2,397

Change To Account Receivables:

$249.61K

Sale Purchase Of Stock:

$45.07M

Capital Expenditures:

$77.06K

M7T Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-594,690

Net Income:

$169.29K

Gross Profit:

$16.45M

Operating Income:

$-925,830

Other Operating Expenses:

$535.18K

Interest Expense:

$43.70K

Income Tax Expense:

$-763,980

Total Revenue:

$18.86M

Cost Of Revenue:

$2.41M

M7T Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$6.94M

Total Liabilities:

$8.15M

Total Stockholder Equity:

$53.47M

Other Current Liabilities:

$2.78M

Total Assets:

$61.62M

Common Stock:

$101.79M

Other Current Assets:

$119.11K

Retained Earnings:

$-51,972,625

Other Liabilities:

$1.44M

Other Assets:

$764.73K

Cash:

$19.32M

Total Current Liabilities:

$6.53M

Property - Plant & Equipment:

$488.24K

Net Tangible Assets:

$46.52M

Total Current Assets:

$53.42M

Net Receivables:

$4.19M

Short-Term Investments:

$8.20M

Accounts Payable:

$1.47M

Non Currrent Assets (Other):

$764.73K

Short-Term Investments:

$8.20

Non Current Liabilities Total:

$1.63M

M7T Share Price History

M7T News

20 Apr, 2021
The big shareholder groups in Mach7 Technologies Limited ( ASX:M7T ) have power over the company. Institutions often...
01 Apr, 2021
This award validates Mach7’s commitment to delivering innovative solutions that give healthcare providers independence and next generation technologies to transform their enterprise imaging strategiesSOUTH BURLINGTON, Vt., April 01, 2021 (GLOBE NEWSWIRE) -- Mach7 Technologies announced that it has been awarded the 2021 Product Leadership Award for Global Enterprise Imaging Solutions by leading business consulting firm Frost & Sullivan. This award validates Mach7’s product and business strategy to combine its industry-leading vendor neutral data management (VNA) and clinical workflow communication applications with the award-winning eUnity diagnostic and enterprise viewing platform (through the acquisition in 2020 of the company, Client Outlook). For industry analysts and healthcare system evaluators, this award confirms the proven value Mach7’s Enterprise Imaging Solution brings to the global healthcare community in driving quality care and patient outcomes in a way that sets it apart from legacy PACS and positions the company for future success. Frost & Sullivan’s Product Leadership Award recognizes the company that offers a product or solution with attributes that deliver the best quality, reliability, and performance in the industry. Frost & Sullivan has identified three key strategic imperatives that impact the digital health industry: disruptive technologies, innovative business models, and transformative Mega Trends. In their view, companies operating in the healthcare IT space must proactively address these three imperatives or risk stagnation or decline. The 2021 Global Enterprise Imaging Solutions Product Leadership Award reflects Mach7’s ability to successfully address these imperatives. The methodology used to evaluate nominees for the award consists of a detailed analysis of best practices criteria across two dimensions: Product Portfolio Attributes and Business Impact. Criteria evaluated under Product Portfolio Attributes include Match to Customer Needs, Reliability and Quality, Product/Service Value, Positioning, and Design. Criteria evaluated under Business Impact include Financial Performance, Customer Acquisition, Operational Efficiency, Growth Potential, and Human Capital. In their analysis, Frost & Sullivan commended Mach7 for excelling in many of these criteria as they pertain to the enterprise imaging solutions space. “Mach7 Technologies’ focus on strategy and innovation coupled with continued enhancement of its customer value is evidenced by its integrated health IT offerings in the medical imaging informatics space,” said Srikanth Kompalli, Program Manager – Medical Imaging & Informatics at Frost & Sullivan. “Driving the shift from legacy departmental PACS to an enterprise-wide imaging system, Mach7 offers differentiated value with a feature-rich zero-footprint universal diagnostic viewer (eUnity platform) and a vendor neutral archive & communication workflow engine that empowers interoperability. Together, these components allow health systems to build and transform their enterprise imaging strategies and ecosystems.” Frost & Sullivan concluded their analysis by stating: "Mach7 stands apart from the competition with a single efficient viewer that provides access to a simplified and centralized data repository that streamlines workflows and reduces service contracts. Mach7 is rapidly emerging as an industry game-changer that is focused on and dedicated to improving the state of the enterprise imaging solution market." “We are delighted to have won this prestigious award from Frost & Sullivan,” said Steve Rankin, Chief Product Officer for Mach7 Technologies. “The powerful combination of the eUnity enterprise and diagnostic viewer and Mach7's flexible data management components gives the company a cohesive Enterprise Imaging Solution that can meet the diverse needs of clinicians and healthcare providers across the enterprise. This award helps validate the innovative strategy we are employing to deliver first-class solutions to the healthcare IT market and helps motivate us to continue delivering high-quality service to our customers.” Mr. Rankin will formally accept the 2021 Global Enterprise Imaging Solutions Product Leadership Award on Mach7’s behalf at Frost & Sullivan’s Virtual Award Ceremony later this year. You can read the full Frost & Sullivan award write-up at mach7t.com/AWARD2021. While you are on our website, be sure to check out our solutions page to learn more about Mach7’s innovative strategy and Enterprise Imaging Solution. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. About Mach7 Technologies Mach7 Technologies develops innovative image management and viewing solutions that form the core of an integrated enterprise imaging ecosystem. Through this innovation, we give healthcare organizations the independence and flexibility to deploy our solutions according to their needs, whether they are in their individual components or unified into a comprehensive end-to-end enterprise imaging platform. Mach7 helps organizations increase their efficiency, achieve profound operational cost savings, leverage their existing IT investments, improve the experience for patients and medical professionals, and support healthier outcomes. Visit Mach7t.com. CONTACT: Bob Tranchida VP of Marketing, Mach7 Technologies 802-861-7745 bob.tranchida@mach7t.com
19 Feb, 2021
Celebrations may be in order for Mach7 Technologies Limited ( ASX:M7T ) shareholders, with the covering analyst...
27 Jan, 2021
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Mach7 Technologies...
16 Nov, 2020
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. You won't get it right...
27 Aug, 2020
Every investor in Mach7 Technologies Limited (ASX:M7T) should be aware of the most powerful shareholder groups...
05 Aug, 2020
BURLINGTON, Vt., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Mach7 Technologies, a leading provider of data management and enterprise imaging solutions for healthcare organizations, announced today that Michigan Medicine has selected Mach7’s eUnity SMARTviewer for enterprise viewing.   Michigan Medicine, which includes the University of Michigan Health System, is the wholly owned academic medical center of the University of Michigan, in Ann Arbor. Delivering advanced clinical care, path-breaking research on human health and disease, and a broad range of biomedical education, Michigan Medicine has been nationally recognized for strong across-the-board performance for 27 consecutive years. They are ranked among the nation’s Honor Roll hospitals and number one in Michigan.eUnity is a powerful zero-footprint viewing and integration platform. It was selected by Michigan Medicine to support enterprise viewing across University of Michigan Medical Center, as well as all primary care, specialty care and affiliate centers. Clinicians will launch eUnity through the Epic patient portal to view up to 1 million studies annually.Mike Lampron, CEO of Mach7 Technologies said, “Michigan Medicine is one of the foremost health systems in America and we are honored to be given their trust as an imaging partner at the enterprise level. We look forward to growing with them as they expand to support patients and communities across the state.”About Mach7 TechnologiesMach7 Technologies (ASX:M7T) develops innovative data management solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7’s award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7’s sophisticated workflow tools, advanced clinical viewing and optimized vendor neutral archiving solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit Mach7t.com.*Client Outlook is a subsidiary of Mach7About Michigan Medicine: At Michigan Medicine, we advance health to serve Michigan and the world. We pursue excellence every day in our three hospitals, 125 clinics and home care operations that handle more than 2.3 million outpatient visits a year, as well as educate the next generation of physicians, health professionals and scientists in our U-M Medical School.Michigan Medicine includes the top ranked U-M Medical School and the University of Michigan Health System, which includes the C.S. Mott Children’s Hospital, Von Voigtlander Women’s Hospital, University Hospital, the Frankel Cardiovascular Center and the Rogel Cancer Center. Michigan Medicine’s adult hospitals were ranked no. 11 in the nation by U.S. News and World Report in 2019-20 and C.S. Mott Children’s Hospital was the only children’s hospital in Michigan nationally ranked in all 10 pediatric specialties analyzed by U.S. News and World Report for 2020-21. The U-M Medical School is one of the nation's biomedical research powerhouses, with total research funding of more than $500 million. More information is available at www.michiganmedicine.org.For more information:Bob Tranchida VP of Marketing, Mach7 Technologies bob.tranchida@mach7t.com 802.861.7745
19 May, 2020
Mach7 Technologies Limited (ASX:M7T) shareholders will have a reason to smile today, with the analysts making...